“We have worked with a number of a different healthcare IR/PR firms in the past. While we were generally happy with the scope and quality of their work, their contacts, etc., none were really able to establish themselves as an integral part of our team. So, when Steve explained to us how Kilmer Lucas was different from most other firms, we were intrigued and, admittedly, a little cautious. We also felt that BioTuesdays might potentially prove to be a powerful tool for gaining additional exposure and properly positioning our investment story, but we weren’t sure. It has been three years now since we engaged Kilmer Lucas, and everything has worked out as Steve promised. He and his team have helped us navigate and communicate through a variety of important and complex issues – from a successful AdCom meeting, to a revised PDUFA date, to FDA approval, to an initial commercial roll-out, to a potential change in a marketing partner, to an expansion of our drug development pipeline – utilizing a proactive and consultative approach. Today, Kilmer Lucas isn’t really our IR firm as much as it is our IR department.”
“Early in my career as an analyst, I was often reluctant to rely on IR professionals in lieu of speaking directly with CEOs or CFOs; however, Steve proved to be one of the rare exceptions to the rule. In my current role as an investor relations professional, I’ve come to appreciate his capabilities even more, especially as it pertains to working with early-stage healthcare companies. Whether it be communicating a clear corporate message, or effectively targeting the appropriate investor base, Steve has a unique skill set acquired over many years of working with such companies.
I think of Steve as one of the better IR professionals out there and look forward to future opportunities to work with him.”
“Kilmer Lucas is one of a kind. Steve and his team are the most dedicated professionals I have ever worked with. At my previous company, they played a key role in helping build the company from development-stage business with a $25 million market cap to a commercial-stage company that was acquired by a large medical device company. Kilmer Lucas acts as an integral part of the company, providing experience, wisdom and good advice whenever needed. Kilmer Lucas has also accumulated a wide range of contacts over years and is happy to leverage them whenever relevant. Their support of the industry via BioTuesdays is well-known and they have earned the respect of scores of people on both the sell- and buy-sides. On a personal level, a partnership with Kilmer Lucas is like a (good) real-life marriage; they will never abandon you in difficult times and will do everything that is in their power to assist, whatever it takes. Kilmer Lucas’ diversified experience with the capital markets (micro- to large-cap) on one hand and the life science industry (pharma, biotech, device, services) on the other is unique, and another of the firm’s advantages is its global approach. I am excited to now be working with Steve again.”